Quarterly report pursuant to Section 13 or 15(d)

DESCRIPTION OF BUSINESS (Details Narrative)

v3.21.2
DESCRIPTION OF BUSINESS (Details Narrative) - USD ($)
 3 Months Ended
Jun. 15, 2021
Jul. 31, 2021
Jul. 31, 2020
Apr. 30, 2021
Subsidiary, Sale of Stock [Line Items]        
Description of novel products   The Company’s primary focus is Alzheimer’s disease (“Alzheimer’s” or “AD”). With two current and future product candidates, Alzamend aims to bring treatments or cures to market as quickly as possible. The Company’s current pipeline consists of two novel therapeutic drug candidates (collectively, the “Technology”): (i) a patented ionic cocrystal technology delivering a therapeutic combination of lithium, proline and salicylate, known as AL001 or LiProSal, through two royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., as licensor, and (ii) a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s, known as AL002 or CA022W, through a royalty-bearing exclusive worldwide license from the same licensor.    
Common stock, par value (in dollars per share)   $ 0.0001    
Net proceeds from common stock   $ 2,000,000  
Series A Preferred Stock [Member]        
Subsidiary, Sale of Stock [Line Items]        
Preferred stock, outstanding       750,000
IPO [Member]        
Subsidiary, Sale of Stock [Line Items]        
Number of share issued 2,500,000      
Number of share exercise 375,000      
Public offering price $ 5.00      
Net proceeds from common stock $ 12,900,000      
IPO [Member] | Series A Preferred Stock [Member]        
Subsidiary, Sale of Stock [Line Items]        
Preferred stock, outstanding   15,000,000    
IPO [Member] | Digital Power Lending [Member]        
Subsidiary, Sale of Stock [Line Items]        
Stock Issued During Period, Shares, Other 2,000,000